中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

25 records (took 0.024 seconds)

    NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    21.
    发明申请
    NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A 审中-公开
    磷酸二酯酶类型10A的新型抑制剂化合物

    公开(公告)号：US20130116241A1

    公开(公告)日：2013-05-09

    申请号：US13660524

    申请日：2012-10-25

    Applicant: Abbott GmbH & Co. KG ,  AbbVie Inc.

    Inventor： Hervé Geneste ,  Michael Ochse ,  Karla Drescher ,  Sean Turner ,  Berthold Behl ,  Loic Laplanche ,  Jürgen Dinges ,  Clarissa Jakob ,  Lawrence Black

    IPC: C07D495/04 ,  C07D471/04 ,  C07D417/14

    CPC classification number: C07D519/00 ,  C07D401/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/048 ,  C07D495/04

    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. wherein Q is O or S, X1 is N or CH, X2 is N or C—R7; X3 is O, S—X4═C(R8)—, where C(R8) is bound to the carbon atom which carries R2, or —X5═C(R9)—, where X5 is bound to the carbon atom which carries R2; X4 is N or C—R9; X5 is N; Het is selected from optionally substituted phenyl, monocyclic hetaryl and fused bicyclic hetaryl; R1 is selected inter alia from hydrogen, halogen, OH, C1-C4-alkyl, trimethylsilyl, C1-C4-alkylsulfanyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, the moiety Y1-Cyc1; R2 is selected inter alia from hydrogen, halogen, OH, C1-C4-alkyl, trimethylsilyl, C1-C4-alkoxy-C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkoxy, C2-C4-alkenyloxy, etc; A represents one of the following groups A1, A2, A3, A4 or A5: where * indicates the points of attachment to Het and to the nitrogen atom, respectively; and where R3 to R9, R3e, R3f, A′, Y1 and Cyc1 are defined in the claims.

    Abstract translation: 本发明涉及式I的新型化合物，其是10A型磷酸二酯酶的抑制剂及其用于制备药物的用途，因此其适用于治疗或控制选自神经障碍和精神疾病的医学病症，用于改善 与这些疾病相关的症状并降低这种疾病的风险。 其中Q为O或S，X1为N或CH，X2为N或C-R7; X3为O，S-X4 = C（R8） - ，其中C（R8）与携带R2的碳原子结合，或-X5 = C（R9） - ，其中X5与携带R2的碳原子结合 ; X4是N或C-R9; X5是N; Het选自任选取代的苯基，单环杂芳基和稠合双环杂芳基; R1特别选自氢，卤素，OH，C 1 -C 4 - 烷基，三甲基甲硅烷基，C 1 -C 4烷基硫烷基，C 1 -C 4 - 烷氧基-C 1 -C 4烷基，C 1 -C 4 - 烷氧基，C 1 -C 4烷氧基 - C1-C4-烷氧基，Y1-Cyc1部分; R2选自氢，卤素，OH，C 1 -C 4 - 烷基，三甲基甲硅烷基，C 1 -C 4 - 烷氧基-C 1 -C 4 - 烷基，C 1 -C 4 - 烷氧基，C 1 -C 4 - 烷氧基-C 1 -C 4烷氧基， C2-C4-烯氧基等; A代表以下组A1，A2，A3，A4或A5：其中*表示分别与Het和氮原子相连的点; 并且在权利要求中定义R3至R9，R3e，R3f，A'，Y1和Cyc1。

    Inhibitor compounds of phosphodiesterase type 10A
    22.
    发明授权
    Inhibitor compounds of phosphodiesterase type 10A 有权

    公开(公告)号：US10308610B2

    公开(公告)日：2019-06-04

    申请号：US15840138

    申请日：2017-12-13

    Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

    Inventor： Hervé Geneste ,  Michael Ochse ,  Karla Drescher ,  Jürgen Dinges ,  Clarissa Jakob

    IPC: C07D217/26 ,  C07D401/06 ,  C07D413/06 ,  C07D401/14 ,  C07D237/32 ,  C07D417/06 ,  C07D409/08 ,  C07D471/04 ,  A61K31/47 ,  C07D217/24 ,  C07D401/12 ,  C07D417/12 ,  C07D409/12

    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. wherein X1 is CH or N, X2 is C—R5 or N, Y is O or S, R1 is inter alia C2-C8-alkyl, C2-C8-alkenyl, C1-C4-fluoroalkyl, C3-C8-cycloalkyl, C5-C8-cycloalkyl carrying a fused benzene ring, or a moiety Z1—Ar1; R2 is a radical of the formula CR21R22R23 or phenyl or 5- or 6-membered hetaryl having 1, 2 or 3 heteroatoms as ring members which are selected from O, S and N, where phenyl and monocyclic hetaryl are unsubstituted or may carry 1, 2 or 3 identical or different substituents Ra, R3 is inter alia hydrogen, C1-C8-alkyl, C2-C8-alkenyl, C1-C4-fluoroalkyl, C3-C8-cycloalkyl, etc, or R2 and R3 together with the nitrogen atom, to which they are bound form an optionally substituted saturated 5- to 7-membered heterocyclic ring which, in addition to the nitrogen atom, may have 1 or 2 further heteroatoms or heteroatom containing groups selected from the group of O, N, S, SO and SO2; R4 is inter alia C1-C4-alkyl, C1-C4-fluoroalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl or Z4—Ar4; R5 is inter alia hydrogen, halogen, C1-C4-alkyl, C1-C4-fluoroalkyl, C1-C4-alkoxy, C1-C4-fluoroalkoxy, —Z5—Ar5, —O—Z5—Ar5, etc; where Z1 to Z5, Ar1 to Ar5, Ra, R21, R22 and R23 are as defined in the claims.

    Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
    25.
    发明授权
    Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor 有权

    公开(公告)号：US09388148B2

    公开(公告)日：2016-07-12

    申请号：US14213169

    申请日：2014-03-14

    Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

    Inventor： Andreas Haupt ,  Jürgen Dinges ,  Liliane Unger ,  Karsten Wicke ,  Robert Van Waterschoot ,  Karla Drescher ,  Ana Relo

    IPC: C07D403/04 ,  A61K31/496 ,  C07D295/155 ,  C07D239/42

    CPC classification number: C07D295/155 ,  A61K31/496 ,  C07D239/42 ,  C07D403/04

    Abstract: The present invention relates to novel acylaminocycloalkyl compounds, in particular to the compounds of the formula I as described herein and to their salts and N-oxides. The compounds possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of the dopamine D3 receptor. In formula I, the variables have the following meanings: m is 1 or 2, n is 1 or 2, A is selected from the group consisting of CH2, CH2CH2, CHFCH2 and CF2CH2, R1 is an oxygen containing cyclic radical selected such as C3-C6 cycloalkyl, which carries one or two oxygen containing radicals selected from the group consisting of OH, C1-C2-alkoxy, fluorinated C1-C2-alkoxy, and a carbonyl oxygen, R2 is selected from the group consisting of hydrogen, OH and fluorine, R3a is selected from the group consisting of hydrogen and methyl, R3b is selected from the group consisting of hydrogen and methyl, R4 is branched C4-C6 alkyl or branched fluorinated C4-C6 alkyl, and R5 is inter alia C1-C6 alkyl, fluorinated C1-C3 alkyl, C1-C2-alkoxy-C1-C4-alkyl, fluorinated C1-C2-alkoxy-C1-C4-alkyl, hydroxy-C1-C4-alkyl, fluorinated hydroxy-C1-C4-alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C3-C5 cycloalkyl, fluorinated C3-C5 cycloalkyl, etc.

Patent Agency Ranking